Biological Perspectives: The Role of Glutamate in Schizophrenia and Its Treatment

Perspectives in Psychiatric Care

Volumn 48, Issue 3, 2012, Pages 125-128

  Steele, Debbie ^a   Moore, Randy L ^a   Swan, Nancy A ^a   Grant, Joan S ^a   Keltner, Norman L ^a  

^a NONE

Author keywords

Glutamate; NMDA receptors; Schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID; AMINO ACID RECEPTOR STIMULATING AGENT; DOPAMINE; GLUTAMIC ACID; GLYCINE; GLYCINE RECEPTOR; METABOTROPIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT;

DRUG POTENTIATION; HUMAN; METABOLISM; NOTE; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; DOPAMINE; EXCITATORY AMINO ACID AGONISTS; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; GLYCINE; HUMANS; RECEPTORS, GLYCINE; RECEPTORS, METABOTROPIC GLUTAMATE; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 84862891772     PISSN: 00315990     EISSN: 17446163     Source Type: Journal    
DOI: 10.1111/j.1744-6163.2012.00333.x     Document Type: Note

References (23)

1. Buchanan, R., Javitt, D., Marder, S., Schooler, N., Gold, J., McMahon, R., ... Carpenter, W. T. (2007). The cognitive and negative symptoms in schizophrenia trial (CONSIST): The efficacy of glutamatergic agents for negative symptoms and cognitive impairments. American Journal of Psychiatry, 154, 1593-1602.
2. Carlsson, M., & Carlsson, A. (1990). Schizophrenia: A subcortical neurotransmitter imbalance syndrome? Schizophrenia Bulletin, 16(3), 425-432.
3. Citrome, L. (2011). Neurochemical models of schizophrenia: Transcending dopamine. Supplement to Current Psychiatry, 10(9), S10-S14.
4. Costa, J., Khaled, E., Sramek, J., Bunney, W. J., & Potkin, S. G. (1990). An open trial of glycine as an adjunct to neuroleptics in chronic treatment-refractory schizophrenics. Journal of Clinical Psychopharmacology, 10, 71-72.
5. Duncan, E. J., Szilagyi, S., Schwartz, M. P., Burgarski-Kirola, D., Kunzova, A., Negi, S., ... Rotrosen, J. P. (2004). Effects of D-cycloserine on negative symptoms in schizophrenia. Schizophrenia Research, 71, 239-248.
6. Eli Lilly and Company. (2009). Lilly announces inconclusive phase II study results for mGlu2/3 at the International Congress on Schizophrenia Research. Retrieved from
7. Ghose, S., Gleason, K., Lewis-Amezcua, K., & Tamminga, C. (2009). Differential expression of metabotropic glutamate receptors 2 and 3 in schizophrenia: A mechanism for antipsychotic drug action? American Journal of Psychiatry, 166, 812-820.
8. Goff, D. C., Lamberti, J. S., Leon, A. C., Green, M. F., Miller, A. L., Patel, J., ... Johnson, S. A. (2007). A placebo-controlled add-on trial of the ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology, 33(3), 465-472.
9. Javitt, D. C., Zylberman, I., Zukin, S. R., Heresco- Levy, U., & Lindenmeyer, J. P. (1994). Amelioration of negative symptoms in schizophrenia by glycine. American Journal of Psychiatry, 151, 1234-1236.
10. Kantrowitz, J. T., & Javitt, D. C. (2011). Glutamate: New hope for schizophrenia treatment. Current Psychiatry, 10(4), 69-74.
11. Kantrowitz, J. T., Malhotra, A. K., Cornblatt, B., Silipo, G., Balla, A., Suckow, R. F., ... Javitt, D. C. (2010). High dose D-serine in the treatment of schizophrenia. Schizophrenia Research, 121(1-3), 125-130. doi:10.1016/j.schres.2010.05.012
12. Krystal, J., Mathew, S., D'Souza, D., Garakani, A., Gunduz-Bruce, H., & Charney, D. (2010). Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists. CNS Drugs, 24(8), 669-693.
13. Lane, H. Y., Huang, C. L., Wu, P. L., Liu, Y. C., Chang, Y. C., Lin, P. Y., ... Tsai, G. (2006). Glycine transporter-1 inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatement of schizophrenia. Biological Psychiatry, 60, 645-649.
14. Nestler, E. J., Hyman, S. E., & Malenka, R. C. (2009). Molecular neuropharmacology: A foundation for clinical neuroscience (2nd ed.). New York: McGraw Hill.
15. Patil, S., Zhang, L., Martenyi, F., Lowe, S., Jackson, K., Andreev, B., ... Schoepp, D. D. (2007). Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized Phase 2 clinical trial. Nature Medicine, 13(9), 1102-1107. doi:10.1038/nm1632
16. Perkins, D. O. (2011). Efficacy of available antipsychotics in schizophrenia. Supplement to Current Psychiatry, 10(9), S15-S19.
17. Seeman, P., Ko, F., & Tallerico, T. (2005). Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics. Molecular Psychiatry, 10, 877-883.
18. Shim, S. S., Hamonds, M. D., & Kee, B. S. (2008). Potentiation of the NMDA receptor in the treatment of schizophrenia: Focused on the glycine site. European Archives of Psychiatry & Clinical Neuroscience, 258(1), 16-27. doi:10.1007/s00406-007-0757-8
19. Stahl, S. (2007). Beyond the dopamine hypothesis to the NMDA glutamate receptor hypofunction hypothesis of schizophrenia. CNS Spectrums, 12(4), 265-268.
20. Tamminga, C. A., Cascella, N. G., Fakouhi, T. D., & Herting, R. L. (1992). Enhancement of NMDA-mediated transmission in schizophrenia. New York: Raven Press.
21. Tiihonen, J., & Wahlbeck, K. (2011). Glutamatergic drugs for schizophrenia (review). The Cochrane Library, 5, 1-67.
22. Tsai, G., Lane, H. Y., Yang, P., Chong, M. Y., & Lange, N. (2004). Glycine transporter-1 inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biological Psychiatry, 55, 452-456.
23. Waziri, R. (1988). Glycine therapy of schizophrenia. Biological Psychiatry, 23, 210-211.